The balance of immune responses: costimulation verse coinhibition

被引:60
作者
Subudhi, SK
Alegre, ML
Fu, YX
机构
[1] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[3] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2005年 / 83卷 / 03期
关键词
costimulation; coinhibition; lymphocytes; B7; family;
D O I
10.1007/s00109-004-0617-1
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Many of the 137 superfamily members (e.g., B7-1, B7-2, ICOS-L, B7-H1, B7-DC) were initially characterized as T cell costimulatory molecules. However, more recently it has become clear they can also coinhibit T cell responses. We review many of the B7 family members, with a particular focus on B7-H1, and examine their role in autoimmunity, transplant rejection, and cancer pathogenesis. It is crucial to understand that many B7 family members have opposing effects on an immune response. This cautions against using clinical immunotherapeutic reagents targeted against these molecules until we gain a better understanding of the circumstances that regulate the outcomes of the T cell response.
引用
收藏
页码:193 / 202
页数:10
相关论文
共 75 条
[1]   Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].
Agata, Y ;
Kawasaki, A ;
Nishimura, H ;
Ishida, Y ;
Tsubata, T ;
Yagita, H ;
Honjo, T .
INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772
[2]   The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice [J].
Ansari, MJI ;
Salama, AD ;
Chitnis, T ;
Smith, RN ;
Yagita, H ;
Akiba, H ;
Yamazaki, T ;
Azuma, M ;
Iwai, H ;
Khoury, SJ ;
Auchincloss, H ;
Sayegh, MH .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (01) :63-69
[3]   CD4+CD25high regulatory cells in human peripheral blood [J].
Baecher-Allan, C ;
Brown, JA ;
Freeman, GJ ;
Hafler, DA .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1245-1253
[4]   Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses [J].
Bennett, F ;
Luxenberg, D ;
Ling, V ;
Wang, IM ;
Marquette, K ;
Lowe, D ;
Khan, N ;
Veldman, G ;
Jacobs, KA ;
Valge-Archer, VE ;
Collins, M ;
Carreno, BM .
JOURNAL OF IMMUNOLOGY, 2003, 170 (02) :711-718
[5]   PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].
Blank, C ;
Brown, I ;
Peterson, AC ;
Spiotto, M ;
Iwai, Y ;
Honjo, T ;
Gajewski, TF .
CANCER RESEARCH, 2004, 64 (03) :1140-1145
[6]   Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism [J].
Blazar, BR ;
Carreno, BM ;
Panoskaltsis-Mortari, A ;
Carter, L ;
Iwai, Y ;
Yagita, H ;
Nishimura, H ;
Taylor, PA .
JOURNAL OF IMMUNOLOGY, 2003, 171 (03) :1272-1277
[7]   CD28 COSTIMULATION CAN PROMOTE T-CELL SURVIVAL BY ENHANCING THE EXPRESSION OF BCL-X(L) [J].
BOISE, LH ;
MINN, AJ ;
NOEL, PJ ;
JUNE, CH ;
ACCAVITTI, MA ;
LINDSTEN, T ;
THOMPSON, CB .
IMMUNITY, 1995, 3 (01) :87-98
[8]   Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production [J].
Brown, JA ;
Dorfman, DM ;
Ma, FR ;
Sullivan, EL ;
Munoz, O ;
Wood, CR ;
Greenfield, EA ;
Freeman, GJ .
JOURNAL OF IMMUNOLOGY, 2003, 170 (03) :1257-1266
[9]  
Carter LL, 2002, EUR J IMMUNOL, V32, P634, DOI 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO
[10]  
2-9